Study finds menbutone boosts albendazole exposure in calves: full analysis

A newly published study in Frontiers in Veterinary Science reports that menbutone coadministration increased systemic exposure to albendazole sulfoxide, the active albendazole metabolite, in calves by about 30%. In the trial, 12 calves received oral albendazole alone or with intramuscular menbutone, and the clearest effect came with a single menbutone dose: mean Cmax rose 33.5% and AUC rose 31.8%. Adding a second menbutone dose 24 hours later did not further improve absorption. (frontiersin.org)

The work lands in a broader context of pressure to get more out of existing antiparasitics. The study authors note that optimizing established anthelmintics has become more important as resistance grows and new antiparasitic development remains slow. That concern is consistent with broader veterinary references documenting benzimidazole resistance and multidrug resistance in livestock parasites, including cattle nematodes in some regions. (frontiersin.org)

The calf study also builds on earlier work from the same research group and related publications in sheep. In sheep, coadministration of menbutone increased albendazole sulfoxide exposure as well, though by a smaller margin than what was reported here in calves. Background literature describes menbutone, also known as genabilic acid, as a choleretic that can increase bile, pancreatic, and peptic secretions by two- to fivefold for a short period after administration, offering a biologically plausible explanation for improved dissolution and absorption of albendazole, a poorly water-soluble drug. (mdpi.com)

In the new calf experiment, blood samples were collected over 72 hours and analyzed by HPLC for albendazole, albendazole sulfoxide, and albendazole sulfone. No parent albendazole was detected at any sampling time, while the active sulfoxide metabolite persisted longer than the inactive sulfone metabolite. The dosing scheme used oral albendazole at 7.5 mg/kg and intramuscular menbutone at 10 mg/kg, with either one or two menbutone administrations. The practical takeaway from the pharmacokinetic data is narrow but clear: one menbutone dose changed exposure, and a second dose did not appear to improve it further. (frontiersin.org)

Outside this paper, the evidence base is still limited. A 2024 study in calves from the same university described menbutone pharmacokinetics in cattle and noted that the drug is used parenterally up to 10 mg/kg, with sparse species-specific pharmacokinetic information otherwise available in product documentation. That paper also pointed to European regulatory history indicating that no maximum residue limit was considered necessary for menbutone in food-producing animals covered by the listing, and an EMA summary report includes bovine, ovine, caprine, porcine, and equine species. (mdpi.com)

Expert reaction specific to this new calf paper appears limited so far, which isn’t unusual for an early pharmacokinetic report. But the authors’ own prior sheep paper characterized the approach as a simple and inexpensive way to increase albendazole exposure, and that framing helps explain why this line of work may draw interest in production-animal medicine. Even so, there’s an important distinction between altering plasma exposure and proving better parasite control in the field. (mdpi.com)

Why it matters: For veterinary professionals, this is best read as a hypothesis-strengthening study rather than a practice-changing one. It suggests that coadministration strategy can influence albendazole pharmacokinetics in calves, which could eventually matter where efficacy is marginal, formulation options are limited, or resistance pressure is pushing clinicians and herd advisors to optimize every treatment decision. But the study does not establish improved clinical efficacy, does not address residue or withdrawal implications for an albendazole-menbutone combination regimen, and does not override the need to follow approved labeling and stewardship principles. Careful dosing remains central, because underdosing is one of the factors associated with accelerating anthelmintic resistance. (frontiersin.org)

What to watch: The next step is straightforward: controlled efficacy studies in naturally infected calves to determine whether the roughly 30% increase in albendazole sulfoxide exposure actually improves parasite reduction, and whether that benefit is large enough to matter in real-world cattle practice. (frontiersin.org)